Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aspirin does not reduce incidence of cognitive decline

Key clinical point: Among healthy adults predominantly aged 70 years and older, low-dose aspirin does not significantly reduce the incidence of dementia, probable Alzheimer’s disease, mild cognitive impairment, or cognitive decline, compared with placebo.

Major finding: During median follow-up of 4.7 years, cognitive change was similar among participants who received aspirin and participants who received placebo. Results did not vary in subgroups of patients.

Study details: A double-blind randomized controlled trial that included more than 19,000 participants.

Disclosures: Bayer provided the trial drug and placebo. The trial was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, the National Health and Medical Research Council of Australia, Monash University, and the Victorian Cancer Agency. Investigators disclosed financial relationships with Bayer and other pharmaceutical companies.

Citation:

Ryan J et al. Neurology. 2020 Mar 25. doi: 10.1212/WNL.0000000000009277.